The utilization of the mRNA-based COVID-19 vaccines has spearheaded the advancement of mRNA research and development. mRNA has shown to be a versatile drug class with the potential to encode antigens, antibodies, and proteins for the development of new vaccines and therapeutics. BioNTech has developed a modular manufacturing platform which harnesses technologies across different drug classes and modalities to create tailored treatment approaches for oncology and infectious diseases. This presentation will highlight the capabilities that BioNTech is bringing to the Australian research industry in partnership with mRNA Victoria to facilitate the translation of mRNA technologies from the bench to the clinic.